每经AI快讯，有投资者在投资者互动平台提问：公司重要产品，达芬奇医疗机器人系统是不是自主研 发，目前专用医用机器人领域占比多少？ 建发致新（301584.SZ）10月20日在投资者互动平台表示，公司目前在达芬奇手术机器人产品经营活动 中，承担分销商角色，该产品品牌系海外Intuitive Surgical, Inc.所有，并非公司研发和生产。公司目前没 有医用机器人方面的技术研发储备和投资计划。 （记者 王瀚黎） ...

Core Points - The company has changed its investor contact number to improve investor relations management [1] - The new investor contact number is 021-60430629, replacing the old number 021-60430840 [1] - Other contact information, such as the company's registered address and email, remains unchanged [1]

Core Viewpoint - The company, Jianfa Zhixin (301584), primarily engages in the distribution and direct sales of medical devices, including high-value medical consumables and IVD diagnostic products, and does not currently involve in the sales of innovative drug projects [1] Group 1 - The main business activities of the company include the distribution and direct sales of medical devices [1] - The company focuses on high-value consumables and IVD diagnostic products [1] - There is no involvement in the sales of innovative drug projects at this time [1]

Core Viewpoint - The company, Jianfa Zhixin (301584), confirmed on October 17 that its subsidiary, Hunan Zhixin Ruichen Information Technology Co., Ltd., is a high-tech enterprise responsible for the company's digital development functions [1] Group 1 - The subsidiary, Hunan Zhixin Ruichen Information Technology Co., Ltd., plays a crucial role in the company's digital transformation efforts [1] - The designation as a high-tech enterprise indicates the subsidiary's focus on innovation and technology [1]

Group 1 - The stock of Jianfa Zhixin increased by 4.20% with a turnover rate of 38.49%, and a total transaction amount of 547 million yuan, showing a fluctuation of 9.40% [1] - Institutional investors net bought 22.81 million yuan, while the total net buying from brokerage seats was 5.35 million yuan [1][2] - The stock was listed on the Shenzhen Stock Exchange due to its high turnover rate, with institutional proprietary seats contributing significantly to the net buying [2] Group 2 - The top five brokerage seats had a combined transaction amount of 107 million yuan, with a net buying of 28.16 million yuan [2] - The main capital inflow for the stock was 40.48 million yuan, with large orders contributing a net inflow of 42.77 million yuan [2] - Over the past five days, the main capital net inflow was 19.95 million yuan [2]

Market Performance - The ChiNext Index fell by 3.36%, closing at 2935.37 points, with a total trading volume of 465.68 billion yuan, a decrease of 11.88 billion yuan from the previous trading day [1] - Among the tradable ChiNext stocks, 132 stocks closed higher, with 5 stocks hitting the daily limit up, while 1254 stocks closed lower, with 5 stocks experiencing a decline of over 10% [1] Turnover Rate - The average turnover rate for the ChiNext today was 3.45%, with 27 stocks having a turnover rate exceeding 20% [1] - The stock with the highest turnover rate was Yunhan Chip City, which closed up 8.72% with a turnover rate of 66.75% and a trading volume of 1.56 billion yuan [1] Sector Analysis - In terms of sector performance, the power equipment industry had the most stocks with a turnover rate exceeding 20%, followed by the electronics and computer sectors [2] Institutional Activity - Five high-turnover ChiNext stocks appeared on the Dragon and Tiger List, with institutional participation noted in several stocks [3] - Jianfa Zhixin had 4 institutional seats with a net purchase of 22.81 million yuan, while Matrix Shares had a net sell of 10.94 million yuan from 4 institutional seats [3] Fund Flow - Among high-turnover stocks, 16 stocks saw net inflows from main funds, with Tongyuan Petroleum, Shuangyi Technology, and Boyuan Shares leading in net inflow amounts [3] - Conversely, Lihexing, New Special Electric, and Sunflower experienced significant net outflows [3] Earnings Forecast - Three high-turnover stocks released earnings forecasts for the first three quarters, all indicating profit growth [4] - Yunhan Chip City is expected to have the highest net profit growth rate of 41.41%, followed by Jianfa Zhixin and Haocreator with expected growth rates of 35.00% and 2.48%, respectively [4]

证券代码：301584 证券简称：建发致新 公告编号：2025-001 上海建发致新医疗科技集团股份有限公司 特此公告。 上海建发致新医疗科技集团股份有限公司董事会 2025 年 10 月 17 日 1 上海建发致新医疗科技集团股份有限公司（以下简称" 公司 "）根据工作 需要，同时为进一步做好投资者关系管理工作，即日起启用新的投资者联系电话， 具体变更情况如下: 原投资者联系电话为：021-60430840 变更后投资者联系电话为：021-60430629 除上述内容变更外，公司注册地址、电子邮箱等其他信息均保持不变。上述 变更自本公告披露起正式生效，新投资者联系电话正式启用，敬请广大投资者注 意，由此带来的不便，敬请谅解。 关于变更投资者联系电话的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 ...

Group 1 - The company, Jianfa Zhixin (301584.SZ), confirmed that its main business involves the distribution and direct sales of medical devices, such as high-value medical consumables and IVD diagnostic products [2] - The company does not engage in the sales of innovative drug projects [2]

Core Viewpoint - The company, Jianfa Zhixin (301584.SZ), confirmed that it does not have any business cooperation or service relationship with Shenzhen Xinkailai, and it does not provide EDA design software to them [2] Company Summary - Jianfa Zhixin responded to an investor inquiry on October 17, clarifying its lack of business ties with Shenzhen Xinkailai [2]

Core Insights - The article highlights the successful listing of Jianfa Zhixin Medical Technology Group on the Shenzhen Stock Exchange, raising a total of 446 million yuan, showcasing the integration of the group's strategy and industry [1] - Jianfa Zhixin has experienced significant growth in the medical device sector, with a net profit increase of over 50% year-on-year in Q1 2025, following steady profit growth in 2023 and 2024 [1][2] Company Overview - Jianfa Group has developed a core development strategy of "professionalism, mutual progress, and sustainability" over 40 years, with business operations extending into supply chain management, urban construction, tourism, healthcare, and emerging industries [1] - The company focuses on the medical device distribution market, primarily engaging in direct sales, distribution, and centralized operation services for medical consumables [2][6] Market Dynamics - The Chinese medical device market has shown rapid growth, with the market size increasing from 370 billion yuan in 2016 to 1,032.8 billion yuan in 2023, reflecting a compound annual growth rate of 15.79%, significantly outpacing the global market growth of 6.01% during the same period [2][4] - The market is projected to reach 1.2 trillion yuan in 2024, indicating strong growth potential [2] Financial Performance - Jianfa Zhixin's revenue has steadily increased, with reported revenues of 11.882 billion yuan, 15.443 billion yuan, and 17.923 billion yuan for 2022, 2023, and 2024 respectively, showing year-on-year growth rates of 29.97% and 16.06% for 2023 and 2024 [4][5] - The net profit for the same years was approximately 189 million yuan, 227 million yuan, and 274 million yuan, with year-on-year increases of 19.90% and 20.68% for 2023 and 2024 [4] Business Model and Strategy - Jianfa Zhixin has established a comprehensive distribution network, providing services to over 3,300 medical institutions across 31 provinces in China, and has formed long-term partnerships with over 100 well-known domestic and international medical device manufacturers [6][8] - The company is actively enhancing its service offerings through the implementation of an SPD management system, which centralizes and refines the management of medical consumables, improving efficiency and reducing costs for healthcare institutions [8] Future Outlook - The company aims to leverage its first-mover advantage and continue expanding its market presence in various medical fields, including IVD, surgical, dental, and ophthalmic devices, while enhancing its information systems and centralized service capabilities [10] - Jianfa Zhixin plans to utilize the funds raised from its IPO to invest in information system upgrades, centralized operation services, and to supplement working capital, aiming to improve its operational efficiency and financial structure [9][10]